利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

59 条记录 (耗时 0.028 秒)

    YEAST-BASED BIOSENSOR
    1.
    发明申请
    YEAST-BASED BIOSENSOR 审中-公开

    公开(公告)号：US20170205401A1

    公开(公告)日：2017-07-20

    申请号：US15324986

    申请日：2015-07-10

    申请人： Northwestern University

    发明人： Keith E.J. Tyo ,  Adebola V. Adeniran ,  John W. Bostick ,  Dante A. Pertusi

    IPC分类号： G01N33/542 ,  C07K14/395

    CPC分类号： G01N33/542 ,  C07K14/395 ,  G01N2333/395

    摘要： Provided herein are compositions and systems comprising yeast-based biosensors (YBBs) and methods of use thereof. In particular, YBBs are provided for the detection and/or quantification of an analyte (e.g., peptide analyte) in a sample (e.g., a biological sample, environmental sample, etc.). In some embodiments, provided herein are diagnostic compositions, devices, and methods comprising yeast-based biosensors (YBBs) engineered to detect analytes (e.g., peptides (e.g., biomarker peptides, etc.), etc.). In some embodiments, YBBs comprise (a) recognition element (e.g., receptor (e.g., modified yeast receptor, etc.), etc.) on the exterior of the biosensor (e.g., for binding and or recognition of the analyte (e.g., peptide)), and (b) a reporter that signals binding or recognition of the analyte. In some embodiments, a recognition element is a cell surface receptor.

    Yeast-based methods of identifying nucleic acids and compounds for treating neurodegenerative diseases
    2.
    发明授权
    Yeast-based methods of identifying nucleic acids and compounds for treating neurodegenerative diseases 有权
    用于鉴定用于治疗神经变性疾病的核酸和化合物的基于酵母的方法

    公开(公告)号：US08580512B2

    公开(公告)日：2013-11-12

    申请号：US13063865

    申请日：2009-11-20

    申请人： Stevan Marcus ,  Galina Gulis ,  P. Connor Johnson

    发明人： Stevan Marcus ,  Galina Gulis ,  P. Connor Johnson

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/04 ,  G01N2333/395 ,  G01N2800/2835

    摘要： The disclosure encompasses methods for the screening of small molecules or nucleic acids that may reverse the inhibition of growth of the unicellular yeast Schizosaccharomyces pombe by rotenone. The use of a yeast as the screening target allows for the high-throughput screening of small molecule and nucleic acid libraries for candidates that may then be screened in animal models as therapeutic agents for the treatment of neurodegenerative diseases. The plant-derived isoflavonoid, rotenone, while only moderately inhibitory to S. pombe cell growth on complex rich medium, is highly inhibitory to growth on synthetic minimal medium. S. pombe cells carrying a deletion in the gene pmk1 are hypersensitive to rotenone. S. pombe, therefore, provides a model for elucidating complex 1-independent targets of rotenone, and can serve as a screening tool for identifying compounds or oligonucleotides potentially able to reverse the effects of rotenone or Parkinson's disease in animal or human subjects.

    摘要翻译： 本公开包括用于筛选小分子或核酸的方法，所述小分子或核酸可以通过鱼藤酮来抑制单细胞酵母粟酒裂殖酵母的生长的抑制。 使用酵母作为筛选靶标允许对可能在动物模型中筛选的候选物的小分子和核酸文库的高通量筛选作为治疗神经变性疾病的治疗剂。 植物来源的异黄酮，鱼藤酮，而对富含复合物的培养基上的S.pombe细胞生长只有适度抑制，对合成基本培养基的生长具有高度的抑制作用。 在基因pmk1中携带缺失的粟酒酵母细胞对鱼藤酮具有过敏性。 因此，S.pombe提供了用于阐明鱼藤酮的复合物1-非依赖性靶标的模型，并且可以用作鉴定在动物或人类受试者中潜在地能够逆转鱼藤酮或帕金森病的作用的化合物或寡核苷酸的筛选工具。

    Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel
    4.
    发明申请
    Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel 有权
    炎性肠病和肠易激综合征IBD-first chek诊断面板

    公开(公告)号：US20040137536A1

    公开(公告)日：2004-07-15

    申请号：US10693377

    申请日：2003-10-24

    发明人： James Hunter Boone ,  David Maxwell Lyerly ,  Tracy Dale Wilkins

    IPC分类号： G01N033/53 ,  G01N033/567

    CPC分类号： G01N33/56972 ,  G01N33/6893 ,  G01N2333/395 ,  G01N2333/79 ,  G01N2469/20 ,  G01N2800/065

    摘要： A method for the differentiation of inflammatory bowel disease (IBD) from irritable bowel disease (IBS) followed by distinguishing ulcerative colitis and Crohn's disease from other gastrointestinal illnesses. This highly differential method first uses the presence of elevated lactoferrin as a marker of intestinal inflammation to differentiate IBD from IBS. Patients suspected of IBD are then analyzed for fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as an indicator of Crohn's disease and fecal anti-neutrophil cytoplasmic antibodies (ANCA) as an indicator of ulcerative colitis. IBD patients are further monitored for intestinal inflammation using fecal lactoferrin to evaluate the effectiveness of medical therapy and to predict relapse. The apparatus comprises either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous lactoferrin, ASCA and ANCA in human feces. The method and apparatus can be used by healthcare providers to identify IBD and distinguish ulcerative colitis from Crohn's disease.

    摘要翻译： 一种从肠易激综合征（IBS）分化炎症性肠病（IBD）的方法，然后区分溃疡性结肠炎和克罗恩病与其他胃肠道疾病。 这种高度差异的方法首先使用升高的乳铁蛋白作为肠炎症的标志物来区分IBD与IBS。 然后分析疑似IBD的患者粪便抗Saccharomyces cerevisiae抗体（ASCA）作为克罗恩病和粪便抗嗜中性粒细胞胞质抗体（ANCA）的指标，作为溃疡性结肠炎的指标。 使用粪便乳铁蛋白进一步监测IBD患者的肠道炎症，以评估药物治疗的有效性并预测复发。 该装置包括定性酶联免疫测定或其他免疫测定，其使用对人免疫球蛋白特异性的抗体来测量人粪便中的总内源性乳铁蛋白，ASCA和ANCA。 该方法和装置可被医疗保健提供者用来识别IBD并将溃疡性结肠炎与克罗恩病区分开来。

    METHODS FOR PROGNOSING THE STATUS OF TUMOR PATIENTS
    8.
    发明申请
    METHODS FOR PROGNOSING THE STATUS OF TUMOR PATIENTS 审中-公开
    预防肿瘤患者状况的方法

    公开(公告)号：US20110003335A1

    公开(公告)日：2011-01-06

    申请号：US12735949

    申请日：2009-02-26

    申请人： Martin Thurnher ,  Reinhold Ramoner

    发明人： Martin Thurnher ,  Reinhold Ramoner

    IPC分类号： C12P21/00 ,  G01N33/68 ,  C07K16/12 ,  C07K16/14

    CPC分类号： G01N33/57407 ,  G01N33/569 ,  G01N2333/26 ,  G01N2333/38 ,  G01N2333/395 ,  G01N2333/40 ,  G01N2469/20 ,  G01N2800/56

    摘要： A method for prognosing the status of a tumor patient is provided, wherein the level of antibodies against Saccharomyces cerevisiae, Candida sp., especially Candida albicans, Aspergillus fumigatus or Klebsiella pneumoniae is determined in said the patient, and prognosing the status of the patient upon the level of these antibodies determined in the patient by determining a better status for a patient with a lower level of these antibodies compared to the average level or by determining a worse status for a patient with a higher level of these antibodies compared to the average level.

    摘要翻译： 提供了一种用于预测肿瘤患者状态的方法，其中在所述患者中确定针对酿酒酵母，假丝酵母​​，特别是白色念珠菌，烟曲霉或肺炎克雷伯氏杆菌的抗体水平，并预测患者的状态 通过与平均水平相比，通过确定具有较低水平的这些抗体的患者的更好状态来确定这些抗体的水平，或者通过确定具有较高水平的这些抗体的患者与平均水平相比更差的状态 。

    Mechanism-based screen for retinoid X receptor agonists and antagonists
    10.
    发明授权
    Mechanism-based screen for retinoid X receptor agonists and antagonists 失效
    类维生素X受体激动剂和拮抗剂的机制筛选

    公开(公告)号：US5714595A

    公开(公告)日：1998-02-03

    申请号：US469120

    申请日：1995-06-06

    申请人： Paul Mak ,  Sotirios K. Karathanasis

    发明人： Paul Mak ,  Sotirios K. Karathanasis

    IPC分类号： C07K14/705 ,  C07K14/775 ,  C12N1/21 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/68 ,  C12R1/19 ,  G01N33/566 ,  C07H21/04

    CPC分类号： G01N33/566 ,  C07K14/70567 ,  C07K14/775 ,  C12Q1/6897 ,  G01N2333/395 ,  G01N2333/70567 ,  G01N2500/00

    摘要： A method is described for screening retinoid X receptor agonists or antagonists using a retinoid X receptor expressed by a yeast expression system to screen a compound having a retinoid X receptor agonist or antagonist activity. Another screen is described for detecting a compound having retinoid X receptor agonist or antagonist activity by: (1) providing a yeast strain which expresses the retinoic acid receptor and activates a reporter plasmid containing apolipoprotein AI gene site A or a mutated variant thereof; (2) incubating the compound in suitable media and a colorless chromogenic substrate; and (3) examining the media for development of color. Mutated variants of apolipoprotein AI gene site A which respond selectively to the retinoid X receptor or respond to receptors other than RXR.alpha. are also described.

    摘要翻译： 描述了使用由酵母表达系统表达的类视黄醇X受体筛选视黄醇X受体激动剂或拮抗剂以筛选具有类视黄醇X受体激动剂或拮抗剂活性的化合物的方法。 描述了另一个用于通过以下方式检测具有类视黄醇X受体激动剂或拮抗剂活性的化合物：（1）提供表达视黄酸受体并激活含有载脂蛋白AI基因位点A或其突变变体的报道质粒的酵母菌株; （2）将化合物在合适的培养基和无色的显色底物中孵育; 和（3）检查媒体的颜色发展。 还描述了对视黄酸X受体或对RXRα以外的受体有反应的载脂蛋白AI基因位点A的突变变体。